Precision oncology-driven real world clinical genomics data mining of MET alterations, TMB, and PD-L1 to empower indication agnostic patient enrollment and combination strategies

Abstract No 5737

^{1#}Zheng Feng, ^{1#}Jean-Christophe Pignon, ²Radwa Sharaf, ³Natalie Romanov, ²Julien Doudement, ²Lee A. Albacker, ¹Neil R. Smith , ⁴Noriaki Kurata, ⁵Nobutoshi Matsushita, ^{3*}Juergen Scheuenpflug


¹Global Clinical Biomarkers and Companion Diagnostics, Translational Medicine, Global Development, EMD Serono, a business of Merck KGaA Darmstadt Germany; ²Foundation Medicine, Cambridge, MA, USA ³Global Clinical Biomarkers and Companion Diagnostics, Translational Medicine, Global Clinical Biomarkers, Translational Medicine, Global Clinical ⁵Research and Development Japan, Merck Biopharma Japan, an affiliate of Merck KGaA, Darmstadt, Germany [#] Presenting author and co-first authors; * Corresponding author

INTRODUCTION

Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest. A thorough real-world molecular genomics based characterization of those tumors would allow the expansion of cancer specific indications that might benefit from MET and checkpoint inhibitors and shed light on exploring clinically efficacious combination strategies. Importantly, such an approach would provide an end-to-end solution that could significantly contribute to clinical translation and/or back translation strategies for innovative cancer therapies.

METHODS

We systemically interrogated FoundationInsights®¹ (Q1 2021) a dataset of real-world molecular genomic tumor profiling from North American patients with cancer, and investigated the prevalence of *MET* amplifications, MET exon 14 skipping and MET fusions prevalence in 62,110 unique patient samples across five indications (lung adenocarcinoma [LUAD], esophageal/ gastroesophageal-junction/ stomach adenocarcinoma [Eso/GEJ/Sto], papillary renal cell carcinoma, hepatocellular carcinoma [HCC] and glioblastoma). *MET* alteration prevalence was further categorized based on tumor cell PD-L1 IHC status (22C3 pharmDx) and TMB status. For the analysis the following clinical biomarker thresholds were employed.



Additionally, comprehensive text mining from clinicaltrials.gov³ were conducted to generate a landscape overview.




Figure 1. MET amplification was the most frequent MET alteration in the cancer types examined • *MET* amplification prevalence ranged from 1.4% in HCC to 4.8% in Eso/GEJ/Sto

- *MET* exon 14 skipping was most frequent in lung adenocarcinoma (2.3%) and rare in other tumors evaluated
- *MET* fusions were rarely observed across indications (≤0.1%) and included: *CAPZA2, HLA-DRB1* and *CD47* (lung adenocarcinoma); TRIM24, TSPAN12, CAPZA2, PTPRZ1 and QKI (glioblastoma); CAV1 and SOX30 (gastric cancer) and SPATS2L (RCC)

RESULTS

Prevalence of *MET amplification* by TMB status across tumor types TMB-High (>10mts/Mb) status by Tumor Type




Figure 2. *MET* amplification prevalence was greater in TMB-High tumors (≥10 mutations/megabase, P<0.05) • In HCC and lung adenocarcinoma MET amplification is more frequently observed in tumors with TMB-High • Only 4 of 400 pRCC were TMB high which might explain the MET amplification prevalence of 0% in that

subgroup

Prevalence of *MET* amplification by PD-L1 status across tumor types




Figure 3. *MET* amplification occurrence was higher in PD-L1 high tumor vs. PD-L1-low or PD-L1-negative tumors (P<0.05)

• MET amplification is more common in PD-L1-positive Eso/GEJ/Sto adenocarcinomas and PD-L1-positive lung adenocarcinoma

Prevalence of *MET amplification* by PD-L1 and TMB status in lung adenocarcinoma




Figure 4. *MET* amplification occurrence was higher in PD-L1-high vs. PD-L1-low or PD-L1-negative lung adenocarcinomas (P<0.05) and was also higher in TMB-high vs TMB-low lung adenocarcinomas

- PD-L1-high expression occurs more frequently in MET amplified than not MET amplified lung adenocarcinomas
- TMB-high occurs more frequently in *MET* amplified than not *MET* amplified lung adenocarcinomas
- Co-occurrence of *MET* amplification and PD-L1-high/TMB-high supports the rationale for combining MET inhibitors with PD-1/PD-L1 blockade in *MET* amplified selected lung adenocarcinoma patients

